Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
NCT01093885 is an interventional trial sponsored by University of Pennsylvania. As of 21 Nov 2026, it is completed. It studies Ambrisentan in Scleroderma and Systemic Sclerosis. The registry lists an enrollment of 15 participants at 1 site in 1 country. The registry lists a start date of 28 Feb 2010 and a primary completion date of 31 Jul 2016.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT01093885 |
| Status | Completed |
| Study type | Interventional trial |
| Lead sponsor | University of Pennsylvania |
| Enrollment | 15 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Scleroderma and Systemic Sclerosis |
| Drugs | Ambrisentan |
| Start | 28 Feb 2010 |
| Primary completion | 31 Jul 2016 |
| Study completion | 31 Jul 2016 |
| Last update posted | 29 Nov 2018 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Chris Derk, MD, MSc
University of Pennsylvania
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Pennsylvania Health System
Philadelphia
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT01093885
Each answer restates registry values shown on this page.
What is NCT01093885?
NCT01093885 is an interventional trial sponsored by University of Pennsylvania. It studies Ambrisentan in Scleroderma and Systemic Sclerosis.
Who leads NCT01093885?
The registry names Chris Derk, MD, MSc (principal investigator, University of Pennsylvania) as the overall official.
Where does NCT01093885 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT01093885 study?
The registered drug and biological interventions are Ambrisentan.
When did NCT01093885 end?
The registry lists a primary completion date of 31 Jul 2016 and a study completion date of 31 Jul 2016. The sponsor last updated the record on 29 Nov 2018.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.